Regeneron Pharmaceuticals, Inc.
NASDAQ:REGNBiotechnology
-$5.45 today
- Market cap
- $97.80B
- Beta
- 0.24
- P/E (TTM)
- 14.2
- EPS (TTM)
- $42.53
- Dividend yield
- 0.60%
Volume 0.70M
Average 0.91M
REGN Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Regeneron Pharmaceuticals, Inc.NASDAQ: REGN
Total Equity · Q2 FY2026 · quarter ended Jun 2026
Total equity rises 5.9% from a year ago
Total equity stood at $31.71B at the end of Q2 FY2026, up 5.9% from a year earlier and up 0.9% from the prior quarter. Over 3 fiscal years it compounded at +11.3% a year.
Context
- Total equity amounted to 76.0% of total assets at the end of Q2 FY2026, down 2.3 pp from a year earlier.
- Total equity increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +5.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 31.26B USD
- Year-over-year change
- +6.5%
- 4-year CAGR
- +13.6%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 31.26B | +6.5% |
| FY2024 | 2024-12-31 | 29.35B | +13.0% |
| FY2023 | 2023-12-31 | 25.97B | +14.6% |
| FY2022 | 2022-12-31 | 22.66B | +20.8% |
| FY2021 | 2021-12-31 | 18.77B | — |
Total Equity vs competitors
How REGN compares with its peers on the latest reported figures
- REGN's Jun 2026 total equity of $31.71B is the 3rd highest of the 9 companies compared; the peer median is $11.72B.
- Its year-over-year change of +5.9% is the 6th highest of 9, against a peer median of +9.6%.
- Total equity amounts to 76.0% of total assets for REGN, versus a peer median of 45.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $51.72B | +12.5% | +9.5% | 43.2% | |
| Jun 2026 | $41.95B | -0.3% | -7.8% | 34.4% | |
| Jun 2026 | $31.71B | +5.9% | +11.3% | 76.0% | |
| Jun 2026 | $18.85B | +6.9% | +10.9% | 58.7% | |
| Jun 2026 | $11.74B | -40.1% | +2.2% | 23.8% | |
| Jun 2026 | $11.69B | +57.4% | +33.2% | 12.2% | |
| Jun 2026 | $5.96B | +12.4% | -40.2% | 47.6% | |
| Mar 2026 | $581.57M | +118.7% | +164.5% | 79.4% | |
| Mar 2026 | $230.47M | -22.8% | +47.0% | 80.0% | |
| Peer median (excluding REGN) | $11.72B | +9.6% | +10.2% | 45.4% | |
Competitors are the stored peer set for REGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2.89B | 3.11B | 2.73B | 2.49B | 3.12B |
| Short-term Investments | 2.81B | 4.64B | 8.11B | 6.52B | 5.49B |
| Net Receivables | 6.04B | 5.33B | 5.67B | 6.21B | 5.74B |
| Inventory | 1.95B | 2.4B | 2.58B | 3.09B | 3.2B |
| Other Current Assets | 0 | 0 | 386.6M | 349.2M | 474.8M |
| Total Current Assets | 14.01B | 15.88B | 19.48B | 18.66B | 18.02B |
| Property, Plant & Equipment (Net) | 3.48B | 3.76B | 4.15B | 4.6B | 5.12B |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 6.7M | 915.5M | 1.04B | 1.15B | 1.26B |
| Long-term Investments | 6.84B | 6.59B | 5.4B | 8.9B | 10.26B |
| Tax Assets | 876.9M | 1.72B | 2.58B | 3.31B | 4.08B |
| Other Non-current Assets | 216.1M | 336.4M | 444.1M | 1.14B | 1.82B |
| Total Non-current Assets | 11.42B | 13.33B | 13.6B | 19.1B | 22.54B |
| Total Assets | 25.43B | 29.21B | 33.08B | 37.76B | 40.56B |
| Account Payables | 564M | 589.2M | 606.6M | 789.5M | 939M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 326.3M | 300K | 0 | 213.2M | 0 |
| Deferred Revenue | 442M | 477.9M | 458.9M | 627.7M | 553M |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | 3.93B | 3.14B | 3.42B | 3.94B | 4.37B |
| Long-term Debt | 1.98B | 1.98B | 1.98B | 1.98B | 1.99B |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 73.3M | 69.8M | 126.7M | 185.7M | 208.7M |
| Other Non-current Liabilities | 680.2M | 638M | 854.1M | 1.57B | 2.02B |
| Total Non-current Liabilities | 2.73B | 3.41B | 3.68B | 4.46B | 4.93B |
| Total Liabilities | 6.67B | 6.55B | 7.11B | 8.41B | 9.3B |
| Common Stock | 100K | 100K | 100K | 100K | 100K |
| Retained Earnings | 18.97B | 23.31B | 27.26B | 31.67B | 35.8B |
| Accumulated OCI | (26.2M) | (238.8M) | (80.9M) | (7.9M) | 77.5M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 18.77B | 22.66B | 25.97B | 29.35B | 31.26B |
| Total Debt | 2.7B | 2.7B | 2.7B | 2.7B | 2.71B |
| Net Debt | (185.9M) | (404.5M) | (27.1M) | 216.2M | (412.2M) |
Regeneron Pharmaceuticals, Inc.
NASDAQ:REGN
Intrinsic Alpha fair value
Locked
Current Price
$945.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.